Lupin receives USFDA approval of sNDA for SOLOSEC

24 Feb 2022 , 01:35 AM

Lupin announced that the US Food and Drug Administration has approved the companys supplemental New Drug Application sNDA to expand the use of SOLOSEC secnidazole in the treatment of bacterial vaginosis BV for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and older Bacterial vaginosis is a common vaginal infection and trichomoniasis is the most common non-viral curable sexually transmitted infection in the US The supplemental adolescent approval enhances SOLOSECs strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV